Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Impact of COVID-19 in patients with multiple myeloma based on a global data network
Joaquín Martínez‐López, Gema Hernández, R. Alonso, et al.
Blood Cancer Journal (2021) Vol. 11, Iss. 12
Open Access | Times Cited: 39

Showing 1-25 of 39 citing articles:

Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)
Evangelos Terpos, Pellegrino Musto, Monika Engelhardt, et al.
Leukemia (2023) Vol. 37, Iss. 6, pp. 1175-1185
Open Access | Times Cited: 33
Follow-up of humoral and cellular immune responses after the third SARS-CoV-2 vaccine dose in multiple myeloma patients
Vincenzo Raimondi, Paola Storti, Rosanna Vescovini, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Risk of diabetes in patients with sleep apnea: Comparison of surgery versus CPAP in a long-term follow-up study
Carlos O'Connor‐Reina, Laura Rodríguez‐Alcalá, José María Ignacio García, et al.
Journal of Otolaryngology - Head and Neck Surgery (2023) Vol. 52, Iss. 1
Open Access | Times Cited: 11
A population-based study on incidence trends of myeloma in the United States over 2000–2020
Seyed Ehsan Mousavi, Mehran Ilaghi, Armin Aslani, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 11
Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral response
Paola Storti, Valentina Marchica, Rosanna Vescovini, et al.
OncoImmunology (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 17
Prevention of infections including vaccination strategies in multiple myeloma
Heinz Ludwig, Shaji Kumar
American Journal of Hematology (2022) Vol. 98, Iss. S2
Open Access | Times Cited: 14
Managing and treating COVID-19 in patients with hematological malignancies: a narrative review and expert insights
Heng Joo Ng, Maaz Kamal Alata, Quang The Nguyen, et al.
Clinical and Experimental Medicine (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 2
Delayed diagnosis resulting in increased disease burden in multiple myeloma: the legacy of the COVID-19 pandemic
Jonathan Carmichael, Frances Seymour, Graham McIlroy, et al.
Blood Cancer Journal (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 7
Large-scale real-life analysis of survival and usage of therapies in multiple myeloma
Nieves Lopez-Munoz, Gema Hernández, Rafael Alonso, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 7
Nationwide implementation of lenalidomide maintenance in multiple myeloma: A retrospective, real‐world study
Mads Harsløf, Iman Chanchiri, Trine Silkjær, et al.
eJHaem (2024) Vol. 5, Iss. 2, pp. 316-324
Open Access | Times Cited: 2
Long term follow-up of humoral and cellular response to mRNA-based vaccines for SARS-CoV-2 in patients with active multiple myeloma
Katia Mancuso, Elena Zamagni, Vincenza Solli, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 6
Management of Hematologic Malignancies in the Era of COVID-19 Pandemic: Pathogenetic Mechanisms, Impact of Obesity, Perspectives, and Challenges
Dimitrios Tsilingiris, Narjes Nasiri‐Ansari, Nikolaos Spyrou, et al.
Cancers (2022) Vol. 14, Iss. 10, pp. 2494-2494
Open Access | Times Cited: 8
Sample average treatment effect on the treated (SATT) analysis using counterfactual explanation identifies BMT and SARS-CoV-2 vaccination as protective risk factors associated with COVID-19 severity and survival in patients with multiple myeloma
Amit Mitra, Ujjal Kumar Mukherjee, Suman Mazumder, et al.
Blood Cancer Journal (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 4
Endothelial injury and dysfunction with emerging immunotherapies in multiple myeloma, the impact of COVID-19, and endothelial protection with a focus on the evolving role of defibrotide
Clifton C. Mo, Edward Richardson, Eleonora Calabretta, et al.
Blood Reviews (2024) Vol. 66, pp. 101218-101218
Open Access | Times Cited: 1
Antibody and T‐cell responses by ultra‐deep T‐cell receptor immunosequencing after COVID‐19 vaccination in patients with plasma cell dyscrasias
Alfred Chung, Barbara L. Banbury, Marissa Vignali, et al.
British Journal of Haematology (2022) Vol. 199, Iss. 4, pp. 520-528
Open Access | Times Cited: 7
Clinical Features and Risk Stratification of Multiple Myeloma Patients with COVID-19
Ruifang Zheng, K Mieth, Christen Bennett, et al.
Cancers (2023) Vol. 15, Iss. 14, pp. 3598-3598
Open Access | Times Cited: 3
COVID-19 in multiple myeloma patients: frequencies and risk factors for hospitalization, ventilatory support, intensive care admission and mortality –cooperative registry from the Grupo Brasileiro de Mieloma Multiplo (GBRAM)
Márcia Garnica, Edvan Crusoé, Glaciano Ribeiro, et al.
Hematology Transfusion and Cell Therapy (2023) Vol. 46, Iss. 2, pp. 153-160
Open Access | Times Cited: 3
Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against COVID-19 for Multiple Myeloma Patients: A Prospective Study in the Omicron Era
Ioannis Ntanasis‐Stathopoulos, Charalampos Filippatos, Maria Gavriatopoulou, et al.
Diseases (2023) Vol. 11, Iss. 3, pp. 123-123
Open Access | Times Cited: 3
Building an i2b2-Based Population Repository for COVID-19 Research
Miguel Pedrera‐Jiménez, Noelia García Barrio, Gema Hernández, et al.
Studies in health technology and informatics (2022)
Open Access | Times Cited: 5
Risk Factors of Infection in Relapsed/Refractory Multiple Myeloma Patients Treated with Lenalidomide and Dexamethasone (Rd) Regimen: Real-Life Results of a Large Single-Center Study
Damian Mikulski, Paweł Robak, Wiktoria Ryżewska, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 19, pp. 5908-5908
Open Access | Times Cited: 5
Impact of the COVID-19 pandemic on the diagnosis and treatment of onco-hematologic patients: a discussion paper
Emilio Bouza, Miguel Martı́n, Jose Enrique Alés, et al.
Revista Española de Quimioterapia (2022) Vol. 36, Iss. 1, pp. 1-25
Open Access | Times Cited: 4
Risk and Severity of COVID-19 Infection in Monoclonal Gammopathy of Undetermined Significance: A 3-Year Propensity Matched Cohort Study
Omer S. Ashruf, Zara Orozco, David C. Kaelber
Clinical Lymphoma Myeloma & Leukemia (2023) Vol. 23, Iss. 8, pp. 626-632
Open Access | Times Cited: 2
Real World Data Integration from Multiple Temporal and Geographical Sources for Clinical Research
Gema Hernández
(2024)
Open Access
Perceptions and realities about early mortality rates from COVID-19 in Indian patients with cancer
Vinayak V Maka, Santhosh K. Devadas
Cancer Research Statistics and Treatment (2022) Vol. 5, Iss. 1, pp. 113-116
Open Access | Times Cited: 3
Impaired acute‐phase humoral immunity is the major factor predicting unfavorable outcomes in multiple myeloma patients with SARS‐CoV‐2 Omicron variants outbreak infection
Ziping Li, Huiwen He, Haolong Li, et al.
International Journal of Cancer (2024) Vol. 155, Iss. 8, pp. 1500-1509
Closed Access
Page 1 - Next Page

Scroll to top